Advertisement

Reactions Weekly

, Volume 1753, Issue 1, pp 81–81 | Cite as

Brigatinib/cetuximab/osimertinib

Chemotherapy resistance secondary to C797S mutation in cis with T790M: case report
Case report
  • 18 Downloads

Reference

  1. Wang X, et al. Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy. Journal of Thoracic Oncology 14: e85-e88, No. 5, May 2019. Available from: URL: http://doi.org/10.1016/j.jtho.2019.01.015 - China

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations